Advertisement


Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax

2023 ASH

Advertisement

Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the Sympatico study, which shows the combination of ibrutinib and venetoclax improved progression-free survival vs ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma. According to Dr. Wang, these findings demonstrate a favorable benefit-risk profile for ibrutinib plus venetoclax in this patient population (Abstract LBA2).



Related Videos

Lymphoma

Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib

Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (Abstract 981).

Leukemia

Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid

Harinder Gill, MD, MBBS, of The University of Hong Kong, discusses findings showing the use of an “AAA” regimen (pure oral arsenic trioxide combined with all-trans retinoic acid) in a risk-adapted strategy that minimized chemotherapy was highly effective and safe in patients with newly diagnosed acute promyelocytic leukemia of all risk categories and age groups. However, he cautions, early deaths remain an obstacle to realizing a cure for all with this disease (Abstract 157).

Hematologic Malignancies

Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool

Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who may benefit from disease-specific therapies or enrollment in clinical trials (Abstract 901).

Leukemia
Lymphoma

William G. Wierda, MD, PhD, on Use of Pirtobrutinib for Richter Transformation: Updated Efficacy and Safety Results

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the phase I/II BRUIN study, which shows encouraging response and overall survival in patients with Richter transformation. Although this condition remains a challenging diagnosis, pirtobrutinib represents a potential treatment option that warrants further investigation, according to Dr. Wierda (Abstract 1737).

Multiple Myeloma

Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab

Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Dr. Dima and her team evaluated the real-world safety and efficacy of this agent and found encouraging evidence of efficacy in a real-world setting (Abstract 91).

Advertisement

Advertisement




Advertisement